Q32 Bio director granted 10,826 stock options

Q32 Bio Inc. director David S. Grayzel received a corrected grant of stock options covering 10,826 shares of common stock at an exercise price of $12.64 per share, expiring on June 11, 2036.

Rhea-AI Filing Summary

Q32 Bio Inc. director David S. Grayzel received a corrected grant of stock options covering 10,826 shares of common stock at an exercise price of $12.64 per share, expiring on June 11, 2036.

The options vest in full on the earlier of June 12, 2027 or the company’s next annual meeting of stockholders, subject to his continued service. Any proceeds from sales of shares issued on exercise will be transferred to Atlas Venture Life Science Advisors, LLC, and Grayzel disclaims beneficial ownership except for any pecuniary interest.

Insider Trade Summary

Grant/Award: 10,826 shares

Grant/Award 1 txn

Insider GRAYZEL DAVID S.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1, F2, F3	10,826	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 10,826 contracts (Direct)

Footnotes (3)

1. F1. This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.
2. F2. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
3. F3. This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Key Figures

Stock options granted: 10,826 shares Exercise price: $12.64 per share Option expiration date: June 11, 2036 +1 more

4 metrics

Stock options granted 10,826 shares Options to purchase common stock granted to director on June 12, 2026

Exercise price $12.64 per share Exercise price for the reported stock option award

Option expiration date June 11, 2036 Expiration date of the granted stock options

Vesting trigger Earlier of June 12, 2027 or next annual meeting Full vesting contingent on continued service through the vesting date

Key Terms

Stock Option (Right to Buy), pecuniary interest, Section 16 of the Securities Exchange Act of 1934, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"The security title is listed as Stock Option (Right to Buy) for common stock."

pecuniary interest financial

"The Reporting Person disclaims ownership except to the extent of his pecuniary interest therein."

Section 16 of the Securities Exchange Act of 1934 regulatory

"Disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934."

A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.

annual meeting of stockholders regulatory

"Vests upon the earlier of June 12, 2027 or the date of the Issuer's next annual meeting of stockholders."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock option grant did Q32 Bio (QTTB) report for David S. Grayzel?

Q32 Bio reported that director David S. Grayzel received 10,826 stock options with an exercise price of $12.64 per share. The options relate to common stock and expire on June 11, 2036, representing a compensation award rather than an open-market trade.

Why was the Q32 Bio (QTTB) Form 4/A amendment filed?

The Form 4/A was filed to correct the number of options awarded to David S. Grayzel on June 12, 2026. The amendment states it is solely to fix that option amount from the earlier Form 4 submitted on June 16, 2026.

When do David S. Grayzel’s QTTB stock options vest?

The options will vest and become exercisable in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders. Vesting is conditioned on Grayzel’s continued service through that vesting date.

Who receives proceeds from any QTTB share sales after these options are exercised?

The filing states that proceeds from any sale of Q32 Bio common stock issued upon option exercise will be transferred to Atlas Venture Life Science Advisors, LLC. Grayzel disclaims beneficial ownership of the reported securities except for any pecuniary interest.

Did the Q32 Bio (QTTB) Form 4/A show any open-market buys or sells of common stock?

No. The Form 4/A reports only a grant of stock options to director David S. Grayzel, with no open-market purchases or sales of Q32 Bio common stock reported in this amendment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/21/2026 - 08:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GRAYZEL DAVID S.

(Last) (First) (Middle)

Q32 BIO INC.

830 WINTER STREET

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Q32 Bio Inc. [ QTTB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
06/16/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.64	06/12/2026		A		10,826(1)		(2)	06/11/2036	Common Stock	10,826(1)	$0	10,826(1)	D(3)

Explanation of Responses:

1. This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.

2. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

3. This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

	/s/ Eric Bell, Attorney-in-Fact	07/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)